Trials / Completed
CompletedNCT04771988
Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis
Trans-arterial Radioembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 17 (actual)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT), Sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (TARE) with yttrium-90 has been also proposed. A considerable percentage of such patients are not only able to achieve stability of the disease, but also to obtain a complete radiological response (CR). The possibility of achieving a CR might allow these patients to be listed for liver transplantation (LT), in order to cure not only the cancer but also the underlying cirrhosis that generated it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | yttrium-90 radioembolization | selective/superselective treatment using resin microspheres labeled with Yttrium-90 |
Timeline
- Start date
- 2013-05-08
- Primary completion
- 2017-05-08
- Completion
- 2020-12-31
- First posted
- 2021-02-25
- Last updated
- 2021-02-25
Source: ClinicalTrials.gov record NCT04771988. Inclusion in this directory is not an endorsement.